Typhoid conjugate vaccine - International Vaccine Institute/Incepta/SK Chemicals/PT Biofarma

Drug Profile

Typhoid conjugate vaccine - International Vaccine Institute/Incepta/SK Chemicals/PT Biofarma

Alternative Names: Vi-DT; Vi-DT conjugated typhoid vaccine

Latest Information Update: 31 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator International Vaccine Institute
  • Developer Incepta Vaccine; International Vaccine Institute; PT Bio Farma; SK Chemicals
  • Class Bacterial vaccines; Drug conjugates
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Typhoid

Most Recent Events

  • 18 Apr 2017 Phase-I clinical trials in Typhoid (Prevention, In volunteers, In children, In adults, In adolescents) in Indonesia (Parenteral) (NCT03109600)
  • 05 Apr 2017 PT Bio Farma plans a phase I trial for Typhoid (Prevention, In children, In adolescents, In adults) (Parenteral) (NCT03109600)
  • 26 Oct 2016 Clinical trials in Typhoid (Prevention) in Bangladesh (Parenteral) before October 2016 (International Vaccine Institute, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top